<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008552</url>
  </required_header>
  <id_info>
    <org_study_id>MEDIAGENE</org_study_id>
    <nct_id>NCT02008552</nct_id>
  </id_info>
  <brief_title>Study of the Effect of the Benfluorex</brief_title>
  <acronym>MEDIAGENE</acronym>
  <official_title>Research for Genetic Factors Involved in the Individual Susceptibility to Develop a Valvulopathy During a Medicinal Exposure in the Benfluorex.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than 5 million persons in France exposed, in last years, to the taking of the&#xD;
      Benfluorex.&#xD;
&#xD;
      Arisen, at certain patients, of a valvulopathy characterized by mitrals and/or aortic leaks&#xD;
      Withdrawal of the French market: nov. 2009 Only a percentage limited by exposed patients&#xD;
      developed a severe valvulopathy (1/1000), whereas on the contrary, many patients were exposed&#xD;
      during years without developing the slightest anomaly.&#xD;
&#xD;
      The hypothesis is the existence of a particular genetic susceptibility at the patients having&#xD;
      developed a valvulopathy continuation in the exposure in this medicine.&#xD;
&#xD;
      Existence of one varying genetics with strong effect. The purpose is to identify involved&#xD;
      genetic factors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2013</start_date>
  <completion_date type="Anticipated">October 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify the genetic factors</measure>
    <time_frame>12 months</time_frame>
    <description>Identify the genetic factors involved in the individual susceptibility to develop a valvulopathy during a medicinal exposure in the benfluorex.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the quality of life of the cases and the witnesses via the completion of Two validated questionnaires of quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Blood Sample</condition>
  <arm_group>
    <arm_group_label>Mediagene</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sampling blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Sampling of blood</intervention_name>
    <description>Sampling of blood was taken and analyse to research factor genetic</description>
    <arm_group_label>Mediagene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria of the cases :&#xD;
&#xD;
          -  Individual presenting a typical medicinal valvulopathy defined by:&#xD;
&#xD;
          -  A previous exposure of at least 6 months in the benfluorex or occasional exposure&#xD;
             accepted about is the posology. The preliminary exposure in the dexfenfluramine or in&#xD;
             the fenfluramine is authorized.&#xD;
&#xD;
          -  A picture board of insufficiency mitral restrictive and/or aortic restrictive (in&#xD;
             echocardiography) typical of a medicinal achievement, a gravity (rank I - IV), without&#xD;
             cause associated of valvulopathy with compatible macroscopic and histological aspect&#xD;
             (for the operated patients).&#xD;
&#xD;
          -  Individual followed in one of the sites of study or recruited via associations AVIM&#xD;
             and CADUS.&#xD;
&#xD;
          -  Individual of Caucasian origin&#xD;
&#xD;
          -  Individual having signed the form of specific consent for the study individual .&#xD;
&#xD;
        Inclusion criteria of witnesses :&#xD;
&#xD;
          -  Individual presenting an exposure previous to the benfluorex superior or equal to the&#xD;
             equivalent of 2 years of treatment in 3 tablets a day and pursued to 2 years preceding&#xD;
             the realization of a cardiac echography of screening. The preliminary exposure in the&#xD;
             dexfenfluramine or in the fenfluramine is authorized.&#xD;
&#xD;
          -  Individual presenting a strictly normal cardiac echography in particular: absence of&#xD;
             valvulopathy significant, of morphological valvular anomaly (event without echography)&#xD;
             and of valvular, including &quot;trivial&quot; leak at the aortic level. The mitrals micro leaks&#xD;
             &quot;physiological&quot; are accepted.&#xD;
&#xD;
          -  Individual having been seen for screening in one of the sites of study or in in French&#xD;
             firms cardilogie which cardiologists are members of the French Society of Cardiologyor&#xD;
             or via the law firms of the civil parties or having been included in the&#xD;
             forward-looking study coordinated by Pr. TRIBOUILLOY (which the objective is to&#xD;
             compare the echography data of a group of patients having been treated at least 3&#xD;
             months in the benfluorex and with a group of patients diabetics having never received&#xD;
             this medicine).&#xD;
&#xD;
          -  Individual of Caucasian origin.&#xD;
&#xD;
          -  Individual having signed the form of specific consent for the study&#xD;
&#xD;
        Exclusion criteria of the cases:&#xD;
&#xD;
          -  Individual presenting another associated heart disorder.&#xD;
&#xD;
          -  Individual having been exposed to another agonists of the receivers 5-HT2B such as the&#xD;
             pergolide, the cabergoline, the lisuride, the quibbled by-products or the ecstasy.&#xD;
&#xD;
          -  Individual having explicitly refused to participate in the study.&#xD;
&#xD;
        Exclusion criteria of witnesses :&#xD;
&#xD;
        - Individual having explicitly refused to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irène Frachon, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Dias</last_name>
    <email>patricia.dias@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irène Frachon, PH</last_name>
    <email>irene.frachon@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Sud Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irène FRACHON, PH</last_name>
    </contact>
    <investigator>
      <last_name>Irène FRACHON, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick Jobic, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves Etienne, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de la Côte de Nacre Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Philibert</name>
      <address>
        <city>Lomme</city>
        <zip>59462</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institut du Thorax Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Faculté de médecine Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31073</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 28, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genetic factor</keyword>
  <keyword>Valvulopathy</keyword>
  <keyword>Mediator</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

